Since SMYD2 is overexpressed in a large proportion of human cancers including colon cancer, breast cancer, and hepatocellular carcinoma, development of novel anti-cancer drugs targeting SMYD2 should be a very effective way to treat various types of human cancer in which the Wnt/β-catenin/TCF pathway is activated. This evidence concerns the gene SMYD2 and breast carcinoma.